Cue Biopharma plunges 23.7% despite positive Phase 2 results
AI Summary- Cue Biopharma dropped 23.7% despite positive Phase 2 clinical results.
- Leveraged ETFs tied to AMD, Strategy and Novo Nordisk fell sharply.
- Biotech stocks and leveraged ETFs were the market’s biggest losers.